---
title: >-
  Anthracyclines / Trastuzumab: new aspects of cardiotoxicity and molecular mechanisms




url: "/publications-1/2015-anthracyclines-trastuzumab-new-aspects-of-cardiotoxicity-and-molecular-mechanisms/"
slug: "anthracyclines-trastuzumab-new-aspects-of-cardiotoxicity-and-molecular-mechanisms"
date: 2015-01-01
lastmod: 2026-01-30T00:06:48+01:00
meta:
  hugo:
    permalink: "/publications-1/2015-anthracyclines-trastuzumab-new-aspects-of-cardiotoxicity-and-molecular-mechanisms/"
    path: "/publications/2015/anthracyclines-trastuzumab-new-aspects-of-cardiotoxicity-and-molecular-mechanisms"
    file: "content/fr/publications/2015/anthracyclines-trastuzumab-new-aspects-of-cardiotoxicity-and-molecular-mechanisms.html"
    slug: "anthracyclines-trastuzumab-new-aspects-of-cardiotoxicity-and-molecular-mechanisms"
  dates:
    created_at: 2025-05-26T10:36:19+02:00
    updated_at: 2026-01-30T00:06:48+01:00
    published_at: 2015-01-01
search:
  id: "2da9ec23-1acc-4bd8-bd3b-7b76879e1675"
  url: "/publications-1/2015-anthracyclines-trastuzumab-new-aspects-of-cardiotoxicity-and-molecular-mechanisms/"
  kind: "Research::Publication"
  title: >-
    Anthracyclines / Trastuzumab: new aspects of cardiotoxicity and molecular mechanisms



breadcrumbs:
  - title: >-
      Accueil
    path: "/"
  - title: >-
      Publications
    path: "/publications-1/"
  - title: >-
      Anthracyclines / Trastuzumab: new aspects of cardiotoxicity and molecular mechanisms

design:
  full_width: true
  toc:
    present: false
    offcanvas: false

hal:
  docid: "3434138"
  url: "https://ube.hal.science/hal-03434138v1"
abstract: >-
  Anticancer drugs continue to cause significant reductions in left ventricular ejection fraction resulting in congestive heart failure. The best-known cardiotoxic agents are anthracyclines such as doxorubicin. For several decades, cardiotoxicity was almost exclusively associated with anthracyclines, for which cumulative dose-related cardiac damage was the use-limiting step. Human epidermal growth factor receptor 2 (HER2; ErbB2) has been identified as an important target for breast cancer. Trastuzumab (TRZ), a humanized anti-HER2 monoclonal antibody, is currently recommended as first-line treatment for patients with metastatic HER2+ tumours. The use of TRZ may be limited by the development of drug intolerance, such as cardiac dysfunction. Cardiotoxicity has been attributed to free-iron-based, radical-induced oxidative stress. Many approaches have been promoted to minimize these serious side effects, but they are still clinically problematic. A new approach to personalized medicine for cancer that involves molecular screening for clinically relevant genomic alterations and genotype-targeted treatments is emerging.
journal_title: >-
  Trends in Pharmacological Sciences
citation_full: >-
  Luc Rochette, Charles Guenancia, Aurélie Gudjoncik, Olivier Hachet, Marianne Zeller, et al.. Anthracyclines / Trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. <i>Trends in Pharmacological Sciences</i>, 2015, 36 (6), pp.326-348. <a target="_blank" href="https://dx.doi.org/10.1016/j.tips.2015.03.005" rel="noreferrer">⟨10.1016/j.tips.2015.03.005⟩ <span class="sr-only">(lien externe)</span></a>. <a target="_blank" href="https://ube.hal.science/hal-03434138v1" rel="noreferrer">⟨hal-03434138⟩ <span class="sr-only">(lien externe)</span></a>
authors_list: >-
  Luc Rochette, Charles Guenancia, Aurélie Gudjoncik, Olivier Hachet, Marianne Zeller, Yves Cottin, Catherine Vergely
ref: >-
  Trends in Pharmacological Sciences, 2015, 36 (6), pp.326-348. ⟨10.1016/j.tips.2015.03.005⟩
links:
  - label: "HAL"
    url: "https://ube.hal.science/hal-03434138v1"
  - label: "DOI"
    url: "https://dx.doi.org/10.1016/j.tips.2015.03.005"
  - label: "URL"
    url: ""
  - label: "PDF"
    url: "https://ube.hal.science/hal-03434138/file/TIPS-VERSION3-2015%20final.pdf"
researchers:
  - charles-guenancia
citations:
  - label: "APA"
    format: "apa"
    content: >-
      Rochette, L., Guenancia, C., Gudjoncik, A., Hachet, O., Zeller, M., Cottin, Y., & Vergely, C. (2015). Anthracyclines / Trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. In <i>Trends in Pharmacological Sciences</i>. https://dx.doi.org/10.1016/j.tips.2015.03.005
  - label: "MLA"
    format: "mla"
    content: >-
      Rochette, Luc, et al. “Anthracyclines / Trastuzumab: New Aspects of Cardiotoxicity and Molecular Mechanisms.” <i>Trends in Pharmacological Sciences</i>, Jan. 2015, https://dx.doi.org/10.1016/j.tips.2015.03.005.
  - label: "Chicago"
    format: "chicago"
    content: >-
      Rochette, Luc, Charles Guenancia, Aurélie Gudjoncik, et al. 2015. “Anthracyclines / Trastuzumab: New Aspects of Cardiotoxicity and Molecular Mechanisms.” In <i>Trends in Pharmacological Sciences</i>. https://dx.doi.org/10.1016/j.tips.2015.03.005.
  - label: "Harvard"
    format: "harvard"
    content: >-
      Rochette, L. <i>et al.</i> (2015) “Anthracyclines / Trastuzumab: new aspects of cardiotoxicity and molecular mechanisms,” <i>Trends in Pharmacological Sciences</i>. Available at: https://dx.doi.org/10.1016/j.tips.2015.03.005.
  - label: "ISO 690"
    format: "iso690"
    content: >-
      ROCHETTE, Luc, GUENANCIA, Charles, GUDJONCIK, Aurélie, HACHET, Olivier, ZELLER, Marianne, COTTIN, Yves and VERGELY, Catherine, 2015. <i>Anthracyclines / Trastuzumab: new aspects of cardiotoxicity and molecular mechanisms</i> [en ligne]. January 2015. Disponible à l'adresse : https://dx.doi.org/10.1016/j.tips.2015.03.005
---